Renhe Partners with Applied Pharma to Market Migraine Drug in China

Renhe Group of Beijing has formed a partnership with Switzerland's Applied Pharma Research to distribute Diclofenac, a patented treatment for migraine, in China, Hong Kong, Macao and Taiwan. APR's product is a powder for oral solution. So far, migraines are not a major problem in China, but the two companies believe the condition may be under-diagnosed because it is uncommon. Over time, they expect the stresses of an increasingly urban China will also cause greater incidence. Financial details of the agreement were not disclosed. More details.... Share this with colleagues: // //